The Docierge Thesis: Why global health intelligence is the most important consumer platform nobody has built yet

The blunt version

One hundred million Americans are drowning in medical debt. The total tab is $195 billion and climbing. Sixty-two percent of personal bankruptcies in this country trace back to a hospital bill.

A knee replacement at Bumrungrad International in Bangkok costs $14,000. The same procedure in Dallas runs $50,000. In Beijing, CAR-T therapy that costs $1,000,000 in the US is available through a clinical trial for approximately $80,000. A monthly supply of semaglutide that costs $1,200 in the US costs $30 in India since the patent expired in March 2026.

The information to make radically better healthcare decisions exists. It is scattered across government databases, academic journals, regulatory filings, and clinical trial registries in a dozen languages across 190 countries. No patient can navigate it. No existing platform assembles it. That is the gap Docierge fills.

What Docierge actually is

Docierge is a global health intelligence membership — the first AI medical concierge platform that answers the three questions every patient deserves answered:

1. What does this procedure actually cost at US hospitals? Using mandatory CMS price transparency data — enforced as of April 1, 2026 — Docierge shows the real median cost, 10th and 90th percentile ranges, pulled from actual remittance records. Not estimates. What hospitals have actually been paid.
2. What does the same procedure cost globally? The same procedure benchmarked against vetted hospitals in Thailand, India, Mexico, South Korea, Germany, and 30+ other destinations. US price and global price, side by side.
3. Is there a better or newer treatment anywhere in the world? A continuously updated RAG-powered AI chatbot covering global medical breakthroughs — clinical trials, peptide therapies, GLP-1 access, CAR-T therapies, stem cell protocols, experimental oncology, and treatments available abroad before domestic approval.

No competitor covers all three. Turquoise Health covers question 1 — for B2B buyers, not patients. OpenEvidence covers question 3 — for physicians, not patients. The consumer-facing intersection of all three has no funded incumbent.

Five forces that make 2026 the right moment

1. US price transparency became real (April 1, 2026)

CMS now requires hospitals to publish actual remittance data — median, 10th percentile, and 90th percentile of what hospitals have actually been paid from the prior 12–15 months. For the first time, an American consumer can see their local hospital charged a median of $47,000 for hip replacement while Bangkok charges $14,000. Docierge is the comparison engine that was waiting for this data to exist.

2. GLP-1 / semaglutide patent expiry (March 2026)

Novo Nordisk's semaglutide patent expired in India. Over 50 manufacturers launched generics at $30/month. The same molecule costs $1,200/month in the US — a 95% price gap. People are already flying to Mexico, Thailand, and India for it.

3. Peptide reclassification under RFK (early 2026)

HHS Secretary Kennedy reclassified 14 previously restricted peptides back to compounding-eligible status: BPC-157, CJC-1295, Ipamorelin, Thymosin Alpha-1, Semax, Selank, AOD-9604, GHK-Cu, and others. Consumer interest in peptide therapy now exceeds Ozempic search volume.

4. China's CAR-T leadership (2026)

China leads the world in CAR-T clinical trials with 850+ ongoing studies vs. fewer than 500 in the US. In 2026, China expects the world's first CAR-T approval for a solid tumor (gastric cancer, Claudin18.2-targeting). Access through Chinese trials: approximately $80,000 vs. $800,000–$1M in the US.

5. The domestic affordability crisis

100 million Americans carry medical debt totaling $195 billion. 41% of US adults owe medical or dental debt. 57% of underinsured adults skipped necessary care due to cost. 2 in 5 reported their health worsened as a result.

The competitive landscape

• Patients Beyond Borders (Directory): No US price data, no AI, no research. Useful like a phone book.
• Medical Departures / Placidway (Marketplace): Earn commissions from hospitals. Recommendations follow money, not outcomes.
• Turquoise Health / Serif Health (B2B Price Transparency): Sophisticated tools for payers and employers. No consumer layer, no international comparison, no research.
• OpenEvidence (Physician AI): $150M ARR, 40% of US physicians — but serves doctors not patients. No cost data. No access guidance.
• Hims & Hers (DTC): Consumer-facing, US-only, no global access, no research layer.
• Docierge: The only platform combining all three layers — CMS prices, global benchmarks, breakthrough research — for consumers. No hospital commissions.

The moat

Three data pipelines that take 18–24 months to replicate at quality: (1) CMS MRF ingestion and structuring — billions of rows of machine-readable hospital pricing data; (2) Vetted international provider database — real cost benchmarks, accreditation, and outcomes across 30+ countries; (3) Multi-jurisdiction research RAG pipeline — PubMed, ClinicalTrials.gov, NMPA (China), EMA, WHO ICTRP, preprint servers with evidence-tier classification.

The deeper moat is the patient health profile database. Every member who builds a condition profile makes the platform smarter. After 12 months of membership, switching costs are real.

The global supply: Hainan Boao Lecheng and beyond

Thailand has 60+ JCI-accredited hospitals. Bumrungrad International treats 500,000 foreign patients annually. India issues e-medical visas to 171 countries. China's Hainan Boao Lecheng Medical Zone recorded 865,000 medical tourism visits in 2025 (up 109% year-over-year), with access to 560+ advanced medicines not approved on the mainland and a zero-tariff policy reducing drug costs ~13%.

Valuation path

Pre-seed (now): $0 ARR, $20M valuation. Seed (Month 6–9): $500K ARR, $50M valuation, $2M raise. Series A (Month 18–24): $8M ARR, $180M valuation. Series B (Month 30–42): $50M ARR, $600M valuation. Series C (Year 4–5): $150M ARR, $2B valuation.

Benchmark: OpenEvidence reached $150M ARR serving physicians. The consumer equivalent — serving patients across price, access, and research — addresses a market 10x larger.

In closing

The American healthcare system is not going to fix itself on any timeline that matters for people suffering under it now. Across the world, hospitals, clinics, pharmacies, and research institutions deliver equal or better outcomes at a fraction of the price — and treatments not yet available domestically. The barrier has never been supply. It has been information. Docierge closes it. Not as a travel agent. Not as a pharmacy. As the intelligence platform that tells you what your procedure costs here, what it costs everywhere, and whether a better treatment exists anywhere in the world. The world's healthcare, in your hands. — www.docierge.icu